Ezabenlimab

埃本利单抗

Report date: 2026/05/28 20:00:21

Base Information

Drug NameEzabenlimab
Drug Alias NameBI-754091
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisSmall Cell Lung Carcinoma +[24] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgNational Health Research InstitutesAmal Therapeutics Sa
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm MetastasisSmall Cell Lung Carcinoma +[19] 
Inactive IndicationsSoft Tissue NeoplasmsBiliary Tract NeoplasmsTriple Negative Breast Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A